Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective.
Coccidioidomycosis cost-effectiveness of therapy
Multi-drug-resistant tuberculosis cost-effectiveness of therapy
Pneumoconiosis cost-effectiveness of therapy
Zygomycosis future or investigational therapies
Leprosy future or investigational therapies
Coccidioidomycosis future or investigational therapies
Tuberculosis cost-effectiveness of therapy
Listeriosis cost-effectiveness of therapy